Minerva Neurosciences (NERV)
(Delayed Data from NSDQ)
$2.80 USD
+0.07 (2.61%)
Updated Sep 24, 2024 12:30 PM ET
3-Hold of 5 3
C Value C Growth D Momentum C VGM
Income Statements
Fiscal Year end for Minerva Neurosciences, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 0 | 0 | 0 | 41 | 0 |
Cost Of Goods | 0 | 0 | 0 | 0 | 0 |
Gross Profit | 0 | 0 | 0 | 41 | 0 |
Selling & Adminstrative & Depr. & Amort Expenses | 23 | 25 | 45 | 39 | 76 |
Income After Depreciation & Amortization | -23 | -25 | -45 | 2 | -76 |
Non-Operating Income | -7 | -7 | -6 | 0 | 1 |
Interest Expense | 0 | 0 | 0 | 0 | 0 |
Pretax Income | -30 | -32 | -52 | 2 | -74 |
Income Taxes | 0 | 0 | -2 | 0 | -2 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -30 | -32 | -50 | 2 | -72 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -30 | -32 | -50 | 2 | -72 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -23 | -25 | -45 | 2 | -76 |
Depreciation & Amortization (Cash Flow) | 0 | 0 | 0 | 0 | -1 |
Income After Depreciation & Amortization | -23 | -25 | -45 | 2 | -76 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 6.51 | 5.34 | 5.34 | 5.12 | 4.88 |
Diluted EPS Before Non-Recurring Items | -4.61 | -6.01 | -4.72 | 0.40 | -14.80 |
Diluted Net EPS (GAAP) | -4.61 | -6.01 | -9.36 | 0.40 | -14.80 |
Fiscal Year end for Minerva Neurosciences, Inc falls in the month of December .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Cost Of Goods | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
SG&A, R&D, and Dept/Amort Expenses | 6.28 | 6.68 | 7.17 | 6.08 | 4.52 |
Income After SG&A, R&D, and Dept/Amort Expenses | -6.28 | -6.68 | -7.17 | -6.08 | -4.52 |
Non-Operating Income | -1.96 | -1.89 | -1.85 | -1.74 | -1.67 |
Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Pretax Income | -8.23 | -8.57 | -9.02 | -7.82 | -6.19 |
Income Taxes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | -8.23 | -8.57 | -9.02 | -7.82 | -6.19 |
Extras & Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | -8.23 | -8.57 | -9.02 | -7.82 | -6.19 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | 7.57 | 7.57 | 7.57 | 7.57 | 5.51 |
Diluted EPS Before Non-Recurring Items | -1.09 | -1.13 | -1.19 | -1.03 | -1.12 |
Diluted Net EPS (GAAP) | -1.09 | -1.13 | -1.15 | -1.03 | -1.12 |